About Ajax Therapeutics
Ajax Therapeutics is a company based in Cambridge (United States) founded in 2019 by Olli Silvennoinen was acquired by Lilly in April 2026. It operates as a HealthTech. Ajax Therapeutics has raised $135 million across 2 funding rounds from investors including Lilly, Schrödinger and Memorial Sloan - Kettering Cancer Center. Ajax Therapeutics offers products and services including AJ1-11095 and AJ1-10502. Ajax Therapeutics operates in a competitive market with competitors including Adicet Bio, ImmunoACT, Orca Bio, Ossium Health and Nordic Nanovector, among others.
- Headquarter Cambridge, United States
- Founders Olli Silvennoinen
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ajax Therapeutics
Ajax Therapeutics offers a comprehensive portfolio of products and services, including AJ1-11095 and AJ1-10502.
A first-in-class Type II JAK2 inhibitor developed.
A next-generation Type II JAK2 inhibitor researched.
Funding Insights of Ajax Therapeutics
Ajax Therapeutics has successfully raised a total of $135M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $95 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ajax Therapeutics
Ajax Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Schrödinger and Memorial Sloan - Kettering Cancer Center.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity firm
|
Locked | Locked | Locked | |
|
Biotech startups are funded by this venture capital firm.
|
Locked | Locked | Locked | |
|
Investment in biotechnology companies is facilitated by this firm.
|
Locked | Locked | Locked |
Investor details for Ajax Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ajax Therapeutics
Investment portfolio details for Ajax Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ajax Therapeutics
Detailed financials for Ajax Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ajax Therapeutics Comparisons
Peer comparison for Ajax Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ajax Therapeutics
Ajax Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adicet Bio, ImmunoACT, Orca Bio, Ossium Health and Nordic Nanovector, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Immune cell therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cell therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| Locked | Locked | Locked |
Ossium Health is focused on bioengineering for improved health.
|
|
| Locked | Locked | Locked |
Antibody radionuclide conjugates are developed for haematological cancers.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for hematopoietic stem cell transplants are developed.
|
Detailed competitors of Ajax Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ajax Therapeutics
Complete news archive for Ajax Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ajax Therapeutics
Ajax Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Ajax Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Ajax Therapeutics is a funded company, having raised a total of $135M across 2 funding rounds to date.
Ajax Therapeutics is engaged in the development of targeted therapies for hematologic cancers, specifically myeloproliferative neoplasms (MPNs) such as myelofibrosis. Advanced computational chemistry and structural biology are utilized throughout the drug discovery process. A new generation of Type II JAK2 inhibitors is being developed to address unmet medical needs by improving therapeutic efficacy and reducing disease persistence. The company operates in the biotechnology sector, partnering with industry leaders like Schrödinger, Inc. to optimize drug-like properties of small molecules. Solutions are aimed at overcoming limitations of existing Type I JAK2 inhibitors through greater precision and selectivity.
Ajax Therapeutics's top competitors include Orca Bio, Ossium Health and Adicet Bio.
Ajax Therapeutics offers AJ1-11095 and AJ1-10502.
Ajax Therapeutics has 10 investors. Key investors include Lilly, Schrödinger, Memorial Sloan - Kettering Cancer Center, RA Capital, and Goldman Sachs Asset Management.